Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact Des Neurotomies Périphériques du Membre supérieur Chez l'Enfant Atteint de Paralysie Cérébrale

NCT07915466 is registered in ClinicalTrials.gov with Hospices Civils de Lyon as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07915466 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Impact Des Neurotomies Périphériques du Membre supérieur Chez l'Enfant Atteint de Paralysie Cérébrale
Lead sponsor
Hospices Civils de Lyon
Phase
Observational
Overall status
Not yet recruiting
Start date
November 15, 2026
Completion date
June 15, 2027
Enrollment
21 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cerebral palsy infantile, upper limb spasticity

Arms

As registered; 1 arm.

  • Children with cerebral palsy who have undergone a peripheral neurotomy of the upper limb. Peripheral neurotomy of the upper limb (musculocutaneous and/or median and/or ulnar).

    Children with cerebral palsy who have undergone a peripheral neurotomy of the upper limb (musculocutaneous and/or median and/or ulnar), assessed preoperatively and 12-15 months after surgery, using a standardised battery of tests performed as part of routine clinical practice.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Melbourne Test - Version 2 (MA2). Data are collected preoperatively and at 12-15 months postoperatively.

    To mesure the impact of a peripheral neurotomy of the upper limb (musculocutaneous and/or median and/or ulnar) in children with CP on range of motion and dexterity.

    The range of motion and dexterity scores from the MA2 are used as the main criteria. The MA2 assesses the quality of unilateral upper limb function during standardized tasks (approach, grasping, release, manipulation). It is intended for children aged 2.5 to 15 years with neurological impairment.

    The assessment is filmed according to a standardized protocol and scored retrospectively from the video. Four scores expressed as percentages are obtained: range of motion, precision, dexterity, and fluidity of movement. The tool has excellent reliability, both intra- (R = 0.97) and inter-examiner (R = 0.95).

Lead sponsor's other trials

Hospices Civils de Lyon, most recent start first.

Similar trials

Same condition (Cerebral Palsy) and phase, most recent start first.